Cell delivery to the central nervous system

Advanced Drug Delivery Reviews

Volumn 42, Issue 1-2, 2000, Pages 81-102

  Shoichet, Molly S ^a   Winn, Shelley R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BRAIN; ENCAPSULATION; NEUROPHYSIOLOGY; NEUROSURGERY; OSMOSIS; PATIENT TREATMENT; POLYMERS; TRANSPLANTATION (SURGICAL);

BLOOD BRAIN BARRIER (BBB); CENTRAL NERVOUS SYSTEM (CNS); POLYMER ENCAPSULATION; THERAPEUTIC MOLECULES;

CONTROLLED DRUG DELIVERY;

LEVODOPA; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; POLYMER;

ANIMAL MODEL; BEHAVIOR; BLOOD BRAIN BARRIER; CELL; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DELIVERY; DRUG DELIVERY SYSTEM; ENCAPSULATION; FETUS CELL; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MICROINJECTION; NEUROLOGIC DISEASE; NONHUMAN; OSMOTIC PUMP; PARKINSON DISEASE; PRIORITY JOURNAL; PUMP; REVIEW; SUSTAINED RELEASE PREPARATION; TECHNOLOGY; TRANSCYTOSIS;

EID: 0034692118     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00055-7     Document Type: Article

References (148)

1. Emerich D., Michael R., Lehman M., Sanberg P. Behavioral effects of neural transplantation. Cell Transplant. 1:1992;401-427.
2. Rubin R.J., Gold W.A. The Cost of Disorders of the Brain. 1992;National Foundation for Brain Research.
3. Nature, 399 (Suppl.) A1-A47.
4. Skaper S.D., Walsh F.S. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Mol. Cell. Neurosci. 12:1998;179-193.
5. Cervos-Navarro J., Kannuki S., Nakagawa Y. Blood-brain barrier (BBB). Review from morphological aspect. Histol. Histopathol. 3:(2):1988;203-213.
6. McComb J.G., Zlokovic B.V. Cerebrospinal fluid and the blood-brain interface. Cheek W.R., Marlin A.E., McLone D.G., Reigel D.H., Walker M.L. Pediatric Neurosurgery. (1994);167-185 W.B. Saunders, Philadelphia.
7. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Ann. Rev. Neurosci. 22:1999;11-28.
8. Dunnett S.B., Bjorklund A. Functional Neural Transplantation. (1994);Raven, New York.
9. Bjorklund A., Schmidt R.H., Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 211:1980;39-45.
10. Lindvall O., Bjorklund A. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials. Acta Neurol. Scand. Suppl. 126:1989;197-210.
11. Freed W.J., Poltorak M., Becker J.B. Intracerebral adrenal medulla grafts: a review. Exp. Neurol. 110:1990;139-166.
12. Yurek D.M., Sladek J.R. Dopamine cell replacement: Parkinson's disease. Annu. Rev. Neurosci. 13:1990;415-440.
13. Emerich D.F., Winn S.R., Christenson L., Palmatier M.A., Gentile F.T., Sanberg P.R. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy. Neurosci. Biobehav. Rev. 16:1992;437-447.
14. Emerich D., Michael R., Lehman M., Sanberg P. Behavioral effects of neural transplantation. Cell Transplant. 1:1992;401-427.
15. Springer J., Collier T., Sladek J. Jr., Loy R. Transplantation of male mouse submaxillary gland increases survival of axotomized basal forebrain neurons. J. Neurosci. Res. 19:1988;291-296.
16. Stromberg I., Wetmore C., Ebendal T., Ernfors P., Persson H., Olson L. Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF. J. Neurosci. Res. 25:1990;405-411.
17. Winn S.R., Hammang J.P., Emerich D.F., Lee A., Palmiter R.D., Baetge E.E. Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proc. Natl. Acad. Sci. USA. 91:1994;2324-2328.
18. Lindner M.D., Kearns C.E., Winn S.R., Frydel B., Emerich D.F. Effects of intraventricular encapsulated hNGF-secreting fibroblasts in aged rats. Cell Transpl. 5:(2):1996;205-223.
19. Kordower J.H., Winn S.R., Liu Y.T., Mufson E.J., Sladek J.R. Jr., Hammang J.P., Baetge E.E., Emerich D.F. The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth. Proc. Natl. Acad. Sci. USA. 91:1994;10898-10902.
20. Schumacher J.M., Short M.P., Hyman B.T., Breakefield X.O., Isacson O. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience. 45:1991;561-570.
21. Frim D., Short M., Rosenberg W., Simpson J., Breakefield X., Isacson O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J. Neurosurg. 78:1993;267.
22. Emerich D.F., Hammang J.P., Baetge E.E., Winn S.R. Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Exp. Neurol. 130:1994a;141-150.
23. Kordower J.H., Goetz C.G., Freeman T.B., Olanow C.W. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp. Neurol. 144:1997;41-46.
24. Emerich D.F., Winn S.R., Hantraye P.M., Peschanski M., Chen E.-Y., Chu Y., McDermott P., Baetge E.E., Kordower J.H. Protective effects of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 386:1997a;395-399.
25. Aebischer P., Schleup M., Deglon N., Joseph J., Hirt L., Heyd B., Goddard M., Hammang J., Zurn A., Kato A., Regli F., Baetge E. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:1996;696-699.
26. Tontsch U., Archer D., Dubois-Dalcq M., Duncan I. Transplantation of an oligodendrocyte cell line leading to extensive myelination. Proc. Natl. Acad. Sci. USA. 91:1994;11616-11620.
27. Duncan I. Glial cell transplantation and remyelination of the central nervous system. Neuropathol. Appl. Neurobiol. 22:1996;87-100.
28. Sagen J., Wang H., Pappas G.D. Adrenal medullary tissue implants in rat spinal cord reduce nociception in a chronic pain model. Pain. 42:1990;69-79.
29. Hama A.T., Sagen J. Reduced pain-related behavior by adrenal medullary transplants in rats with experimental pain neuropathy. Pain. 52:1993;223-231.
30. Aebischer P., Buschser E., Joseph J., Favre J., deTribolet N., Lysaght M., Rudnick S., Goddard M. Transplantation in humans of encapsulated xenogeneic cells without immunosuppression - a preliminary report. Transplantation. 58:1994;1275-1277.
31. Wang H., Sagen J. Attenuation of pain-related hyperventilation in adjuvant arthritis rats with adrenal medullary transplants in the spinal sub-arachnoid space. Pain. 63:1995;313-320.
32. Friden P.M., Walus L.R., Watson P., Doctrow S.R., Kozarich J.W., Backman C., Bergman H., Hoffer B., Bloom F., Granholm A.C. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science. 259:1993;373-377.
33. Friden P.M. Receptor-mediated transport of therapeutics across the blood-brain barrier. Neurosurgery. 35:1994;294-298.
34. 125I] glial cell line- derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. Neurosci. Lett. 220:1996;187-190.
35. Kroll R.A., Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 42:1998;1083-1099.
36. Kordower J.H., Mufson E.J., Granholm A.C., Hoffer B., Friden P. Delivery of trophic factors to the primate brain. Exp. Neurol. 124:1993;21-30.
37. Riddle D.R., Katz L.C., Lo D.C. Focal delivery of neurotrophins into the central nervous system using fluorescent latex microspheres. Biotechniques. 23:(5):1997;928-937.
38. Mufson E.J., Kroin J.S., Sendera T.J., Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol. 57:(4):1999;451-484.
39. Vahlsing H.L., Varon S., Hagg T., Fass-Holmes B., Dekker A., Mamley M., Mansthorpe M. An improved device for continuous intraventricular infusions prevents the introduction of pump-derived toxins and increases the effectiveness of NGF treatments. Exp. Neurol. 105:1989;233-243.
40. Olson L., Backlund E.O., Ebendal T., Freedman R., Hamberger B., Hansson P., Hoffer B., Lindblom U., Meyerson B., Stromberg I. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Arch. Neurol. 48:1991;373-381.
41. Hoffman D., Wahlberg L., Aebischer P. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria- fornix lesion. Exp. Neurol. 110:(1):1990;39-44.
42. Langer R., Moses M. Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J. Cell. Biochem. 45:(4):1991;340-345.
43. Lindner M., Winn S., Baetge E., Hammang J., Gentile F., Doherty E., McDermott P., Frydel B., Ullman M., Schallert T., Emerich D. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp. Neurol. 132:1995;62-76.
44. Sinson G., Voddi M., McIntosh T. Combined fetal neural transplantation and nerve growth factor infusion: effects on neurological outcome following fluid-percussion brain injury in the rat. J. Neurosurg. 84:(4):1996;655-662.
45. Martinez-Serrano A., Bjorklund A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci. 16:(15):1996;4604-4616.
46. Tusznski M., Weidner N., McCormack M., Miller I., Powell H., Conner J. Grafts of genetically modified Schwann cells to the spinal cord: survival, axon growth, and myelination. Cell Transpl. 7:(2):1998;187-196.
47. McTigue D., Homer P., Stokes B., Gage F. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci. 18:(14):1998;5354-5365.
48. Zlokovic B.V., Apuzzo M.L.J. Cellular and molecular neurosurgery: Part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery. 40:1997;805-812.
49. Bowers W., Howard D., Federoff H. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Exp. Neurol. 144:(1):1997;58-68.
50. Kaplitt M., Darakchiev B., During M. Prospects for gene therapy in pediatric neurosurgery. Ped. Neurosurg. 28:(1):1998;3-14.
51. Barkats M., Bilang-Bleuel A., Buc-Caron M.H., Castel-Barthe M.N., Corti O., Finiels F., Horellou P., Revah F., Sabate O., Mallet J. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases. Prog. Neurobiol. 55:(4):1998;333-341.
52. Banks W., Kastin A. Peptide transport systems for opiates across the blood- brain barrier. Neurosurgery. 259:1990;E1-E10.
53. Pardridge W. Peptide Drug Delivery To the Brain. (1991);149-189 Raven Press, New York.
54. Broadwell R. Endothelial cell biology and the enigma of transcytosis through the blood- brain barrier. Adv. Exp. Med. Biol. 331:1993;137-141.
55. Broadwell R., Balm B., Salcman M. Transcytotic pathway for blood-borne protein through the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 85:1988;632-636.
56. Jefferies W., Brandon M., Hunt S., Williams S., Gatter K., Mason D. Transferrin receptor on endothelium of brain capillaries. Nature. 312:1984;162-163.
57. Fishman J., Rubin J., Handrahan J., Connor J., Fine R. Receptor-mediated trancytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18:1987;299-304.
58. Friden P., Walus L., Musso G., Taylor M., Malfroy B., Starzyk R. Antitransferrin receptor antibody and antibody-drug, conjugates, cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 88:1991;4771-4775.
59. Kordower J., Charles V., Bayer R., Bartus R., Putney S., Walus L., Friden P. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington's disease. Proc. Natl. Acad. Sci. USA. 91:1994;9077-9080.
60. Rapoport S. Blood-Brain Barrier in Physiology and Medicine. 1976;Raven Press, New York.
61. Blasberg R., Groothuis D., Molnar P. A review of hyperosmotic blood- brain barrier disruption in seven experimental brain tumor models. Johansson B.B., Owman C., Widner H. Pathophysiology of the Blood-Brain Barrier. (1990);197-220 Elsevier, Amsterdam.
62. Dahlborg S., Henner W., Crossen J., Tableman M., Petrillo A., Braziel R., Neuwelt E. Non-ADS primary CNS lymphoma: the first examples of durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J. Sci. Am. 2:1996;166-174.
63. 125I] nerve growth factor in the rat brain following a single intraventricular injection correlation with the topographical distribution of trkA messenger RNA-expressing cells. Neuroscience. 54:1993;445-460.
64. Lapchak P., Beck K., Araujo D., Irwin I., Langston J., Hefti F. Chronic intranigral administration of brain-derived neurotrophic factors produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medical forebrain bundle transection. Neuroscience. 53:1993;639-650.
65. Yan Q., Matheson C., Sun J., Radeke M., Feinstein S., Miller J. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp. Neurol. 127:1994;23-36.
66. Anderson K., Alderson R., Altar C., DiStefano P., Corcoran T., Lindsay R., Wiegand S. Differential distribution of exogenous BDNF, NGF, and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity and low- affinity neurotrophin receptors. J. Comp. Neurol. 357:1995;296-317.
67. Olson L., Bjorklund A., Hoffer B., Palmer M., Seiger A. Spinal cord grafts: an intraocular approach to enigmas of nerve growth regulation. Brain Res. Bulletin. 9:(1-6):1982;519-537.
68. Granholm A.C. Hippocampal transplants in oculo: a model for establishment of isolated circuits. Conn P.M. Methods in Neuroscience. Vol. 7:1991;327-345 Academic, San Diego.
69. Granholm A., Gerhardt G., Bygdeman M., Stromberg I. Human fetal xenografts of brainstem tissue containing locus coeruleus neurons: functional and structural studies of intraocular grafts in athymic nude rats. Exp. Neurol. 118:(1):1992;7-17.
70. Eriksdotter-Nilsson M., Skirboll S., Ebendal T., Olson L. Nerve growth factor can influence growth of cortex cerebri and hippocampus: evidence from intraocular grafts. Neuroscience. 30:1989;755-766.
71. Backman C., Biddle O., Ebendal T., Friden P., Gerhardt G., Henry M., Mackerlova L., Soderstrom S., Stromberg I., Walus L., Hoffer B., Granholm A. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo. Exp. Neurol. 132:1995;1-15.
72. Brem H., Tamargo R., Olivi A., Pinn M., Weingart J., Wharam M., Epstein J. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J. Neurosurg. 80:(2):1994;283-290.
73. Ommaya A. Implantable devices for chronic access and drug delivery to the central nervous system. Cancer Drug Deliv. 1:(2):1984;169-179.
74. Stahl S. Applications of new drug delivery technologies to Parkinson's disease and dopaminergic agents. J. Neural Trans. Suppl. 27:1988;123-132.
75. Schwab M. Experimental aspects of spinal cord regeneration. Current Opin. Neurol. Neurosurg. 6:(4):1993;549-553.
76. Hagg T., Vahlsing H., Manthrope M., Varon S. Nerve growth factor infusion into the denervated adult rat hippocampal formation promotes its cholinergic reinnervation. J. Neurosci. 10:1990;3087-3092.
77. Lu X., Hagg T. Glial cell line-derived neurotrophic facto prevents death, but not reductions in tyrosine hydroxylase of injured nigrostriatal neurons in adult rats. J. Comp. Neurol. 388:1997;484-494.
78. Kearns A., Gash D. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:1995;104-111.
79. Hagg T., Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl. Acad. Sci. USA. 90:1993;6315-6319.
80. Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol. 149:(1):1998;183-192.
81. Williams L., Inouye G., Cummins V., Pelleymounter M. Glial cell line derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmacol. Exp. Ther. 277:1996;1140-1151.
82. Oudega M., Hagg T. Neurotrophins promote regeneration of sensory axons in the adult rat spinal cord. Brain Res. 818:1999;431-438.
83. Dahm P., Nitescu P., Appelgren L., Curelaru I. Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and/or bupivacine in refractory nonmalignant pain: a comparison between the epidural and the intrathecal approach with externalized or implanted catheters and infusion pumps. Clin. J. Pain. 14:1998;4-16.
84. Angel I., Gould H. Jr., Carey M. Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg. Neurol. 49:1998;92-98.
85. DeYebens J.G., Fahn S., Mena M.A., Pardo B., Casarejos M.J. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates: an experimental approach to the treatment of Parkinson's disease. Trans. Am. Soc. Artif. Intern. Organs. 34:1988;951-957.
86. Bear M., Kleinschmidt A., Gu Q., Singer W. Disruption of experience-dependent synaptic modifications in striate cortex by infusion of an NMDA receptor antagonist. J. Neurosci. 10:(3):1990;909-925.
87. McRae-Degueurce A., Hjorth S., Dillon D., Maso D., Tice T. Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. Neurosci. Lett. 92:(3):1988;303-309.
88. Winn S.R., Aebischer P., Galletti P.M. Brain tissue reaction to permselective polymer capsules. J. Biomed. Mater. Res. 23:1989;31-44.
89. Freese A., Sabel B., Saltzman W., During M., Langer R. Controlled release of dopamine from polymeric brain implant: in vitro characterization. Exp. Neurol. 103:1989;234-238.
90. Cao X., Shoichet M. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials. 20:1999;329-339.
91. Becker J., Robinson T., Barton P., Sintov A., Siden R., Levy R. Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Res. 508:1990;60-64.
92. Sanberg P., Emerich D., Aebischer P., Amisetti S., Ouellette W., Koutouzis T., Cahill D., Norman A. Substance P containing polymer implants protect against striatal excitotoxicity. Brain Res. 628:1993;327-329.
93. Kokaia M., Aebischer P., Elmer E., Bengzon J., Kalen P., Kokaia Z., Lindvall O. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp. Brain Res. 100:1994;385-394.
94. Krewson C., Dause R., Michele M., Saltzman W. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomater. Sci. Polym. Ed. 8:1996;103-117.
95. Brem H., Mahaley M. Jr., Vick N., Black K., Schold S. Jr., Burger P., Friedman A., Ciric I., Eller T., Cozzens J., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74:(3):1991;441-446.
96. Dunnett S. Is it possible to repair the damaged prefrontal cortex by neural tissue transplantation? Prog. Brain Res. 85:1990;285-297.
97. Dunnett S., Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 399:(6738 Suppl):1999;A32-39.
98. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 247:1990;574-577.
99. Langston J.W. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age old debate. Ann. Neurol. 44:(suppl.):1998;S45-S52.
100. Perlow M.J., Freed W.J. W., Seiger A., Olson L., Wyatt R.J. Wyat. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 204:1979;643-647.
101. Bjorklund A., Dunnett S.B., Stenevi U., Lewis M.E., Iversen S.D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimtor testing. Brain Res. 199:1980;307-333.
102. Bakay R.A., Barrow D.L., Fiandaca M.S., luvone P.M., Schiff A., Collins D.C. Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation. Ann. NY Acad. Sci. 495:1987;623-640.
103. Lindvall O. Neural transplantation: a hope for patients with Parkinson's disease. Neuroreport. 8:1997;iii-x.
104. Willing A.E., Othberg A.I., Saporta S., Anton A., Sinibaldi S., Poulos S.G., Cameron D.E., Freeman T.B., Sanberg P.R. Sertoli cells enhance the survival of cotransplanted dopamine neurons. Brain Res. 822:1999;246-250.
105. Rosenblad C., Martinez-Serrano A., Bjorklund A. Glia cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience. 75:1996;979-985.
106. Boonman Z., Isacson O. Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Exp. Neurol. 156:1999;1-15.
107. Carpenter M.K., Winkler C., Fricker R., Emerich D.F., Wong S.C., Greco C., Chen E.Y., Chu Y., Kordower J.H., Messing A., Bjorklund A., Hammang J.P. Generation and transplantation of EGF-responsive neural stem cells derived from GFAPhNGF transgenic mice. Exp. Neurol. 148:1997;187-204.
108. Watts R.L., Subramanian T., Freeman A., Goetz C.G., Penn R.D., Stebbins G.T., Kordower J.H., Bakay R.A. Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two-year follow-up study. Exp. Neurol. 147:1997;510-517.
109. Borlongan C.V., Saporta S., Sanberg P.R. Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promote long-term functional recovery in hemiparkinsonian rats (published erratum appears in Exp. Neurol. (1998) 154, 259). Exp. Neurol. 151:1998;203-214.
110. Svendsen C.V., Caldwell M.A., Shen J., ter Borg M.G., Rosser A.E., Tyers P., Karmiol S., Dunnett S.B. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp. Neurol. 148:1997;135-146.
111. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., Edge A., Penney D., Kassissieh S., Dempsey P., Isaacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. 3:1997;350-353.
112. Butler D. Last chance to stop and think on risks of xenotransplants. Nature. 391:1998;320-324.
113. Trojanowski J.Q., Kleppner S.R., Hartley R.S., Miyazono M., Fraser N.W., Kesari S., Lee V.M.-Y. Transfectable and transplantable postmitotic human neurons: a potential 'platform' for gene therapy of nervous system diseases. Exp. Neurol. 144:1997;92-97.
114. Watanabe R., Takase-Yoden S., Ikeda T., Atsumi T. Gene transfer through implantation of embryonal carcinoma cells in the brain. Cell Transplant. 5:(suppl.):1996;S9-S12.
115. Wachtel S.R., Bencsics C., Kang U.J. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J. Neurochem. 69:1997;2055-2063.
116. Shoichet M.S., Gentile F.T., Winn S.R. The use of polymers in the treatment of neurological disorders. Trends Polym. Sci. 3:1995;374-380.
117. Lim F., Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science. 210:1980;908-910.
118. Crooks C.A., Douglas J.A., Broughton R.L., Sefton M.V. Microencapsulation of mammalian cells in a HEMA-MMA copolymer: effects on capsule morphology and permeability. J. Biomed. Mater. Res. 24:1990;1241-1262.
119. Aebischer P., Winn S.R., Galletti P. Transplantation of neural tissue in polymer capsules. Brain Res. 448:1988;364-368.
120. Shoichet M.S., Rein D.H. In vivo biostability of a polymeric hollow fiber membrane for cell encapsulation. Biomaterials. 17:1996;285-290.
121. Shoichet M.S., Li R.H., White M.L., Winn S.R. Stability of hydrogels used in cell encapsulation: an in vitro comparison of alginate and agarose. Biotechnol. Bioeng. 50:1996;374-381.
122. Haralson M.A. Extracellular matrix and growth factors: an integrated interplay controlling tissue repair and progression to disease. Lab. Invest. 69:1993;369-372.
123. Aebischer P., Tresco P.A., Sagen J., Winn S.R. Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats. Brain Res. 560:1991;43-49.
124. Emerich D.F., Frydel B.R., Flanagan T.R., Palmatier M., Winn S.R., Christenson L. Transplantation of polymer encapsulated PC12 cells: use of chitosan as an immobilization matrix. Cell Transplant. 2:1993;241-249.
125. Massia S.P., Hubbell J.A. Covalent surface immobilization of Arg-Gly-Aspand Tyr-Ile-Gly-Ser-Arg-containing peptides to obtain well-defined cell-adhesive substrates. Anal. Biochem. 187:1990;292-299.
126. Tong Y.W., Shoichet M.S. Peptide surface modification of poly(tetrafluoroethylene-co-hexafluoroethylene) enhances its interaction with central nervous system neurons. J. Biomed. Mater. Res. 42:1998;85-95.
127. Bellamknoda R., Ranieri J.P., Aebischer P. Laminin oligopeptide derivatized agarose gels allow three-dimensional neurite extension in vitro. J. Neurosci. Res. 41:1995;501-509.
128. Tresco P., Winn S., Aebischer P. Polymer encapsulated neurotransmitter secreting cells:potential treatment for Parkinson's disease. American Society for Artificial Internal Organs. 38:1992;17-23.
129. Roberts T., DeBoni U., Sefton M.V. Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate-methyl methacrylate copolymer. Biomaterials. 17:1996;267-275.
130. Aebischer P., Goddard M., Signore P., Timpson R. Functional recovery in hemiparkinsonian primates transplanted with polymer encapsulated PC12 cells. Exp. Neurol. 126:1994;1-12.
131. Subramanian T., Emerich D.F., Bakay R.A.E., Hoffman J.M., Goodman M.M., Shoup T.M., Miller G.W., Levey A.I., Hubert G.W., Batchelor S., Winn S.R., Saydoff J.A., Watts R.L. Polymer-encapsulated PC12 cells demonstrate high affinity uptake and dopamine in vitro and 18F-dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant. 6:1997;469-477.
132. Kordower J.H., Liu Y.-T., Winn S.R., Emerich D.F. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical and neurochemical analysis. Cell Transplant. 4:1995;155-171.
133. Pundt L.L., Join E.A., Conrad J.A., Low W.C. Organization and histochemical phenotype of human fetal cerebellar cells following transplantation into the cerebellum of nude mice. Cell Transplant. 6:1997;479-489.
134. Bernstein-Goral H., Bregman B.S. Axotomized rubrospinal neurons rescued by fetal spinal cord transplants maintain axon collaterals to rostral CNS targets. Exp. Neurol. 148:1997;13-25.
135. Sieradzan B., Vrbova G. Observations on the survival of grafted embryonic motoneurons in the spinal cord of developing rats. Exp. Neurol. 122:1993;223-231.
136. Hammang J.P., Archer D.R., Duncan I.D. Myelination following transplantation of EGF-responsive neural stem cells into a myelin-deficient environment. Exp. Neurol. 147:1997;84-95.
137. Buchanan J.T., Nornes H.O. Transplants of embryonic brainstem containing the locus coeruleus into spinal cord enhance the hindlimb flexion reflex in adult rats. Brain Res. 381:1986;225-236.
138. Commissiong J.W., Sauve Y. The physiological basis of transplantation of fetal catecholaminergic neurons in the transected spinal cord of the rat. Comp. Biochem. Physiol. 93A:1989;301-307.
139. Emerich D.F., Winn S.R., Harper J., Hammang J.P., Baetge E.E., Kordower J.H. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 349:1994b;148-164.
140. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
141. Emerich D.F., Lindner M.D., Winn S.R., Chen E.-Y., Frydel B.R., Kordower J.H. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16:1996;5168-5181.
142. Shoichet M.S., Winn S.R., Athavale S., Harris J.M., Gentile F.T. Poly(ethylene oxide)-grafted thermoplastic membranes for use as cellular hybrid bioartificial organs in the central nervous system. Biotechnol. Bioeng. 43:1994;563-572.
143. Winn S.R., Zielinski B., Tresco P.A., Signore A.P., Jaeger C.B., Greene L.A., Aebischer P. Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells. Exp. Neurol. 113:1991;322-329.
144. Tresco P.A., Winn S.R., Jaeger C.B., Greene L.A., Aebischer P. Polymer-encapsulated PC12 cells: longterm survival and associated reduction in lesioned-induced rotational behavior. Cell Transplant. 1:1992;255-264.
145. Lindner M.D., Emerich D.F. Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease. Cell Transplant. 7:1998;165-174.
146. Lindner M.D., Plone M.A., Mullins T.D., Winn S.R., Chandonait S.E., Stott J.A., Blaney T.J., Sherman S.S., Emerich D.F. Somatic delivery of catecholamines in the striatum attenuate Parkinsonian symptoms and widen the therapeutic window of oral Sinemet in rats. Exp. Neurol. 145:1997;130-140.
147. Winn S.R., Lindner M.D., Lee A., Haggett G., Francis J.M., Emerich D.F. Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences. Exp. Neurol. 140:1996;126-138.
148. Gage F.H. Cell therapy. Nature. 392:(suppl.):1998;18-24.